Big Molecules Biopharmaceuticals

Cell culture, particularly mammalian cell culture, processes enable the production of new, hitherto unknown drugs, the biopharmaceuticals. The year 2001 marked a turning point in the development of biopharmaceuticals, insofar as it was the first time that more new biological entities (NBEs) than 

Fine Chemicals The Industry and the Business, by Peter Poliak Copyright 2007 by John Wiley Sons, Inc. 

The pros and cons of an involvement of a fine-chemical company in cell culture technology are listed below  

Rapidly expanding market—growth rate 10-15% per annum (pharma overall 9%). One-quarter of development drugs are biopharmaceuticals. 

Asian competition is lagging behind. Examples for emerging companies are Biocon, India and Celltrion, South Korea. 

---